High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation

John W. Sweetenham, Angelo M. Carella, Golnaz Taghipour, David Cunningham, Robert Marcus, Aldo Della Volpe, David C. Linch, Norbert Schmitz, Anthony H. Goldstone

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Purpose: To investigate the results of high-dose therapy and autologous stem-cell transplantation (ASCT) in adults with Hodgkin's disease who do not enter remission after induction therapy, to determine overall survival (OS) and progression free survival (PFS), and to identify prognostic factors. Patients and Methods: A retrospective analysis of 175 patients reported to the European Group for Blood and Marrow Transplantation between November 1979 and October 1995. One hundred were male and 75 were female, with a median age of 26.5 years. Responses to first-line therapy were defined as progressive disease (PD) in 88 and stable/minimally responsive disease (SD/MR) in 87. Seventy-five patients received ASCT after failure of one induction regimen. Second-line therapy was given to the remaining 100 patients. Response to second-line therapy was PD in 34 and SD/MR in 66. OS and PFS rates were determined, and prognostic factors were investigated using univariate and multivariate analyses. Results: Responses to high-dose therapy and ASCT were complete response (30%), partial response (28%), no response (14%), PD (14%), and toxic death (14%). Actuarial 5-year OS and PFS rates were 36% and 32%, respectively. In univariate analysis for PFS and OS, adverse factors were use of a second-line chemotherapy regimen and interval of more than 18 months between diagnosis and ASCT. In multivariate analysis, the interval between diagnosis and ASCT maintained prognostic significance for OS. Response to the chemotherapy regimen given immediately before ASCT had no predictive value. Conclusion: High-dose therapy and ASCT is an effective treatment strategy for patients with Hodgkin's disease for whom induction chemotherapy fails. Outcome was equivalent for those with obvious PD or SD/MR in response to the regimen given immediately before high-dose therapy. Prospective randomized studies are required to compare this approach with conventional-dose salvage therapy.

Original languageEnglish
Pages (from-to)3101-3109
Number of pages9
JournalJournal of Clinical Oncology
Volume17
Issue number10
Publication statusPublished - Oct 1999

Fingerprint

Remission Induction
Induction Chemotherapy
Stem Cell Transplantation
Hodgkin Disease
Disease-Free Survival
Survival
Therapeutics
Multivariate Analysis
Survival Rate
Drug Therapy
Salvage Therapy
Poisons
Prospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy : Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. / Sweetenham, John W.; Carella, Angelo M.; Taghipour, Golnaz; Cunningham, David; Marcus, Robert; Della Volpe, Aldo; Linch, David C.; Schmitz, Norbert; Goldstone, Anthony H.

In: Journal of Clinical Oncology, Vol. 17, No. 10, 10.1999, p. 3101-3109.

Research output: Contribution to journalArticle

Sweetenham, John W. ; Carella, Angelo M. ; Taghipour, Golnaz ; Cunningham, David ; Marcus, Robert ; Della Volpe, Aldo ; Linch, David C. ; Schmitz, Norbert ; Goldstone, Anthony H. / High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy : Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 10. pp. 3101-3109.
@article{a542667b0bfd4ba48ca94b3c50d1d501,
title = "High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation",
abstract = "Purpose: To investigate the results of high-dose therapy and autologous stem-cell transplantation (ASCT) in adults with Hodgkin's disease who do not enter remission after induction therapy, to determine overall survival (OS) and progression free survival (PFS), and to identify prognostic factors. Patients and Methods: A retrospective analysis of 175 patients reported to the European Group for Blood and Marrow Transplantation between November 1979 and October 1995. One hundred were male and 75 were female, with a median age of 26.5 years. Responses to first-line therapy were defined as progressive disease (PD) in 88 and stable/minimally responsive disease (SD/MR) in 87. Seventy-five patients received ASCT after failure of one induction regimen. Second-line therapy was given to the remaining 100 patients. Response to second-line therapy was PD in 34 and SD/MR in 66. OS and PFS rates were determined, and prognostic factors were investigated using univariate and multivariate analyses. Results: Responses to high-dose therapy and ASCT were complete response (30{\%}), partial response (28{\%}), no response (14{\%}), PD (14{\%}), and toxic death (14{\%}). Actuarial 5-year OS and PFS rates were 36{\%} and 32{\%}, respectively. In univariate analysis for PFS and OS, adverse factors were use of a second-line chemotherapy regimen and interval of more than 18 months between diagnosis and ASCT. In multivariate analysis, the interval between diagnosis and ASCT maintained prognostic significance for OS. Response to the chemotherapy regimen given immediately before ASCT had no predictive value. Conclusion: High-dose therapy and ASCT is an effective treatment strategy for patients with Hodgkin's disease for whom induction chemotherapy fails. Outcome was equivalent for those with obvious PD or SD/MR in response to the regimen given immediately before high-dose therapy. Prospective randomized studies are required to compare this approach with conventional-dose salvage therapy.",
author = "Sweetenham, {John W.} and Carella, {Angelo M.} and Golnaz Taghipour and David Cunningham and Robert Marcus and {Della Volpe}, Aldo and Linch, {David C.} and Norbert Schmitz and Goldstone, {Anthony H.}",
year = "1999",
month = "10",
language = "English",
volume = "17",
pages = "3101--3109",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy

T2 - Results in 175 patients reported to the European Group for Blood and Marrow Transplantation

AU - Sweetenham, John W.

AU - Carella, Angelo M.

AU - Taghipour, Golnaz

AU - Cunningham, David

AU - Marcus, Robert

AU - Della Volpe, Aldo

AU - Linch, David C.

AU - Schmitz, Norbert

AU - Goldstone, Anthony H.

PY - 1999/10

Y1 - 1999/10

N2 - Purpose: To investigate the results of high-dose therapy and autologous stem-cell transplantation (ASCT) in adults with Hodgkin's disease who do not enter remission after induction therapy, to determine overall survival (OS) and progression free survival (PFS), and to identify prognostic factors. Patients and Methods: A retrospective analysis of 175 patients reported to the European Group for Blood and Marrow Transplantation between November 1979 and October 1995. One hundred were male and 75 were female, with a median age of 26.5 years. Responses to first-line therapy were defined as progressive disease (PD) in 88 and stable/minimally responsive disease (SD/MR) in 87. Seventy-five patients received ASCT after failure of one induction regimen. Second-line therapy was given to the remaining 100 patients. Response to second-line therapy was PD in 34 and SD/MR in 66. OS and PFS rates were determined, and prognostic factors were investigated using univariate and multivariate analyses. Results: Responses to high-dose therapy and ASCT were complete response (30%), partial response (28%), no response (14%), PD (14%), and toxic death (14%). Actuarial 5-year OS and PFS rates were 36% and 32%, respectively. In univariate analysis for PFS and OS, adverse factors were use of a second-line chemotherapy regimen and interval of more than 18 months between diagnosis and ASCT. In multivariate analysis, the interval between diagnosis and ASCT maintained prognostic significance for OS. Response to the chemotherapy regimen given immediately before ASCT had no predictive value. Conclusion: High-dose therapy and ASCT is an effective treatment strategy for patients with Hodgkin's disease for whom induction chemotherapy fails. Outcome was equivalent for those with obvious PD or SD/MR in response to the regimen given immediately before high-dose therapy. Prospective randomized studies are required to compare this approach with conventional-dose salvage therapy.

AB - Purpose: To investigate the results of high-dose therapy and autologous stem-cell transplantation (ASCT) in adults with Hodgkin's disease who do not enter remission after induction therapy, to determine overall survival (OS) and progression free survival (PFS), and to identify prognostic factors. Patients and Methods: A retrospective analysis of 175 patients reported to the European Group for Blood and Marrow Transplantation between November 1979 and October 1995. One hundred were male and 75 were female, with a median age of 26.5 years. Responses to first-line therapy were defined as progressive disease (PD) in 88 and stable/minimally responsive disease (SD/MR) in 87. Seventy-five patients received ASCT after failure of one induction regimen. Second-line therapy was given to the remaining 100 patients. Response to second-line therapy was PD in 34 and SD/MR in 66. OS and PFS rates were determined, and prognostic factors were investigated using univariate and multivariate analyses. Results: Responses to high-dose therapy and ASCT were complete response (30%), partial response (28%), no response (14%), PD (14%), and toxic death (14%). Actuarial 5-year OS and PFS rates were 36% and 32%, respectively. In univariate analysis for PFS and OS, adverse factors were use of a second-line chemotherapy regimen and interval of more than 18 months between diagnosis and ASCT. In multivariate analysis, the interval between diagnosis and ASCT maintained prognostic significance for OS. Response to the chemotherapy regimen given immediately before ASCT had no predictive value. Conclusion: High-dose therapy and ASCT is an effective treatment strategy for patients with Hodgkin's disease for whom induction chemotherapy fails. Outcome was equivalent for those with obvious PD or SD/MR in response to the regimen given immediately before high-dose therapy. Prospective randomized studies are required to compare this approach with conventional-dose salvage therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032887877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032887877&partnerID=8YFLogxK

M3 - Article

C2 - 10506605

AN - SCOPUS:0032887877

VL - 17

SP - 3101

EP - 3109

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -